Increased microvascular permeability in the hamster cheek pouch induced by oxidized low density lipoprotein (oxLDL) and some fragmented apolipoprotein B proteins

Inflammation Research

Volumn 52, Issue 5, 2003, Pages 215-220

  Svensjo E ^b   Boschcov, P ^a   Ketelhuth, D F J ^a   Jancar, S ^a   Gidlund, M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Histamine; oxLDL; PAF; Plasma leakage; Postcapillary venules

Indexed keywords

APOLIPOPROTEIN B; BEPAFANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; N(G) NITROARGININE METHYL ESTER; OXIDIZED LOW DENSITY LIPOPROTEIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CHEEK POUCH; CONTROLLED STUDY; GEL PERMEATION CHROMATOGRAPHY; HAMSTER; MALE; MICROCIRCULATION; NONHUMAN; OXIDATION; PROTEIN ANALYSIS;

EID: 0038174686     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110300074     Document Type: Article

References (35)

1. Frostegård J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc. Natl. Acad Sci. USA 1990; 87: 904-8.
2. Frostegård J, Kjellman B, Gidlund M, Andersson B, Jindal S, Kiessling R. Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein and Interleukin-1: Implications for atherosclerosis. Atherosclerosis 1996; 121: 93-103.
3. Stemme, S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 1995; 92: 3893-7.
4. Chisolm GM, Ma G, Irwin KC, Martin LL, Gunderson KG, Linberg LF et al. 7-β-Hydroperoxycholest-5-en-3-β-ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein. Proc. Natl. Acad Sci. USA 1994; 91: 11452-6.
5. Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial cells. J. Clin. Invest. 1992; 90: 1138-44.
6. Chisolm GM. 1993. Oxidized lipoproteins and leukocyte-endothelial interactions: growing evidence for multiple mechanisms. Lab. Invest. 1993; 68: 369-71.
7. Frostegård J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991; 90: 119-26.
8. Piha M., Lindstedt L, and Kovanen PT. Fusion of proteolyzed low-density lipoprotein in the fluid phase: A novel mechanism generating atherogenic lipoprotein particles. Biochemistry 1995; 34: 10120-9.
9. Lehr H-A, Seemüller J, Hübner C, Menger MD, Messmer K. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet-activating factor. Arterioscler. Thromb. 1993; 13: 1013-8.
10. Lehr H-A, Frei B, Olofsson AM, Carew TE, Arfors KE: Protection from oxidized LDL-induced leukocyte adhesion to microvascular and macrovascular endothelium in vivo by vitamin C but not by vitamin E. Circ.1995; 91: 1525-32.
11. Liao L, Granger DN: Role of mast cells in oxidized low-density lipoprotein-induced microvascular dysfunction. Am. J. Physiol. 1996; 271: H1795-800.
12. Liao L, Harris NR, Granger DN: Oxidized low-density lipoproteins and microvascular responses to ischemia-reperfusion. Am. J. Physiol. 1996; 271: H2508-14.
13. Liao L, Starzyk RM, Granger DN: Molecular determinants of oxidized low-density lipoprotein-induced leukocyte adhesion and microvascular dysfunction. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 437-44.
14. Napoli C, Postiglione A, Triggiani M, Corso G, Palumbo G, Carbone V et al. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia. Atherosclerosis. 1995; 118: 259-73.
15. Sutherland WH. Oxidation of heparin-isolated LDL by hemin. The effect of serum components. Arterioscler Thromb. 1994; 14: 1966-75.
16. Wieland H, and Seidel D, A simple specific method for precipitation of low density lipoproteins. J. Lipid. Res.1983; 24: 904-9.
17. Esterbauer, H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad. Biol. Med. 1992; 13: 341-90.
18. Duling BR. The preparation and use of the hamster cheek pouch for studies of the microcirculation. Microvasc. Res. 1973; 5: 423-9.
19. 2a-induced macromolecular leakage in the hamster cheek pouch. Prostaglandins and Medicine. 1978; 1: 397-410.
20. Svensjö E. The hamster cheek pouch as a model in microcirculation research. Eur. Respir J. 1990; 3: 595-601.
21. Grönneberg R, Strandberg K, Hagermark Effect of terbutaline, a beta 2-adrenergic receptor stimulating compound, on cutaneous responses to histamine, allergen, compound 48/80, and trypsin. Allergy 1979; 34: 303-9.
22. Svensson C, Greiff L, Andersson M, Alkner U, Grönneberg R, Persson CG. Antiallergic actions of high topical doses of terbutaline in human nasal airways. Allergy 1995; 50: 884-900.
23. Ross R. The pathogenesis of atherosclerosis-an update. N. Engl. J. Med.1986; 314: 488-500.
24. Klabunde RE, Anderson DE. Obligatory role of nitric oxide in platelet-activating factor-induced microvascular leakage. Eur. J. Pharmacol. 2000; 22: 387-94.
25. Duran WN, Seyama A, Yoshimura K, Gonzalez DR, Jara PL, Figueroa XF et al. Stimulation of NO production and of eNOS phosphorylation in the microcirculation in vivo. Microvasc. Res. 2000; 60: 104-11.
26. Marathe GK, Davies SS, Harrison KA, Silva AR, Murphy RC, Castro-Faria-Neto H et al. Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J. Biol. Chem. 1999; 274: 28395-404.
27. Persson CGA and Svensjö E. Vascular responses and their suppression: drugs interfering with venular permeability. In: Handbook of Inflammation, Vol. 5, The Pharmacology of Inflammation, Editors: I.L. Bonta, M.A. Bray and M.J. Parnham. Elsevier, Amsterdam, pp. 61-82, 1985.
28. Grega G, Persson CGA, Svensjö E. Endothelial cell reactions to inflammatory mediators assessed in vivo by fluid and solute flux analysis. In: Endothelial Cells. 1988: Vol. III, chapter 35, p. 103-122, 1988. Editor: U.S. Ryan, CRC Press, Boca Raton, Florida, USA.
29. Grönneberg R, Strandberg K. Effect of terbutaline on cutaneous responses in man to rechallenge with allergen and compound 48/80. Allergy 1981; 36: 33-8.
30. Persson NH, Erlansson M, Svensjö E, Takolander R, Bergqvist D. The hamster cheek pouch - an experimental model to study postischemic macromolecular permeability. Int. J. Microcirc. Clin. Exp. 1985; 4: 257-63.
31. Ishida T, Yarimizu K, Gute DC, Korthuis RJ. Mechanisms of ischemic preconditioning. Shock 1997; 8: 86-94.
32. Kubes P, Payne D, Ostrovsky L. Preconditioning and adenosine in I/R-induced leukocyte endothelial cell interactions. Am. J. Physiol. 1998; 274: H1230-H1238.
33. Rangaswamy S, Penn MS, Saidel GM, Chisolm GM. Exogenous oxidized low-density lipoprotein injures and alters the barrier function of endothelium in rats in vivo. Circulation Research 1997; 80: 37-44.
34. Louis RE, Radermecker MF. Acute bronchial obstruction following inhalation of PAF in asthmatic and normal subjects: comparison with methacholine. Eur. Respir. J. 1996; 9: 1414-20.
35. Mills PC, Ng JC, Seawright AA, Auer DE. Kinetics, dose response, tachyphylaxis and cross-tachyphylaxis of vascular leakage induced by endotoxin, zymosan-activated plasma and platelet-activating factor in the horse. J. Vet. Pharmacol. Ther. 1995; 18: 204-9.